Condition: Narcolepsy Type 1 · Narcolepsy Type 2 · Idiopathic Hypersomnia · Sponsor: Alkermes, Inc.
The purpose of this study is to continue to measure the safety, tolerability, and durability of treatment effect in subjects with Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), or Idiopathic Hypersomnia (IH) when taking ALKS 2680 tablets.
This description comes directly from the study's public registry record.
Director, Global Clinical Services · 888-235-8008 (US Only) · clinicaltrials@alkermes.com
Director, Global Clinical Services · 571-599-2702 (Global) · clinicaltrials@alkermes.com
Always discuss trial participation with your own doctor first.
| Alkermes Investigator Site | Phoenix, Arizona, United States | Recruiting |
| Alkermes Investigational Site | Little Rock, Arkansas, United States | Recruiting |
| Alkermes Investigational Site | Los Angeles, California, United States | Recruiting |
| Alkermes Investigator Site | San Francisco, California, United States | Recruiting |
| Alkermes Investigational Site | Stanford, California, United States | Recruiting |
| Alkermes Investigational Site | Colorado Springs, Colorado, United States | Recruiting |
| Alkermes Investigational Site | Brandon, Florida, United States | Recruiting |
| Alkermes Investigational Site | Miami, Florida, United States | Recruiting |
| Alkermes Investigational Site | Winter Park, Florida, United States | Recruiting |
| Alkermes Investigational Site | Atlanta, Georgia, United States | Recruiting |
| Alkermes Investigational Site | Macon, Georgia, United States | Recruiting |
| Alkermes Investigational Site | Stockbridge, Georgia, United States | Recruiting |
+ 34 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06767683